Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003

Clinical Infectious Diseases

Volumn 41, Issue 5, 2005, Pages 599-608

  Richter, Sandra S ^a   Heilmann, Kristopher P ^a   Beekmann, Susan E ^a   Miller, Norma J ^a   Miller, Ashley L ^a   Rice, Cassie L ^a   Doern, Christopher D ^b   Reid, Sean D ^b   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFDINIR; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; PENICILLIN DERIVATIVE; TELITHROMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DIFFUSION; ERMA GENE; ERMB GENE; GENE SEQUENCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEFA GENE; NEWBORN; NONHUMAN; PHARYNX; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS PYOGENES; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; MACROLIDES; MIDDLE AGED; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 23844555181     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432473     Document Type: Article

References (41)

1. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000; 45:3-12.
2. Kim S, Yong Lee N. Epidemiology and antibiotic resistance of group A streptococci isolated from healthy schoolchildren in Korea. J Antimicrob Chemother 2004; 54:447-50.
3. Hsueh P-R, Chen H-M, Huang A-H, Wu J-J. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995; 39:2239-42.
4. Bandak SI, Turnak MR, Allen BS, Bolzon LD, Preston DA. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries. Int J Clin Prac 2000; 54:585-8.
5. Baquero F, Garcia-Rodriguez JA, De Lomas JG, Aguilar L. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43:178-80.
6. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999; 18:1069-72.
7. Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp. collected in the SENTRY antimicrobial surveillance program-North America, 2001. Diagn Microbiol Infect Dis 2003; 46:291-4.
8. Tanz RR, Shulman ST, Shortridge VD, et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis 2004; 39:1794-801.
9. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200-6.
10. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999; 37:1727-31.
11. Green M, Martin JM, Barbadora KA, Beall B, Wald ER. Reemergence of macrolide resistance in pharyngeal isolates of group A streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 2004; 48:473-6.
12. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniaeand S. pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40:1817-24.
13. Seppala H, Skurnik M, Soini H, Roberts MC, Huovinen. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42:257-62.
14. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-92.
15. Malbruny B, Nagai K, Coquemont M, et al. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother 2002; 49:935-9.
16. Bingen E, Leclercq R, Fitoussi F, Brahimi N, Malbruny B, Deforche D, Cohen R. Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002; 46:1199-203.
17. Ruoff KL, Wiley RA, Beighton D. Streptococcus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Vol 1. Washington, DC: ASM Press, 2003:405-21.
18. CLSI (formerly NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A6. 6th ed. Wayne, PA: NCCLS, 2003.
19. CLSI. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. M100-S15. Wayne, PA: CLSI, 2005.
20. Jenssen WD, Thakker-Varia S, Dubin DT, Weinstein MP. Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci. Antimicrob Agents Chemother 1987; 31:883-8.
21. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40:2562-6.
22. Bingen E, Fitoussi F, Doit C, et al. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 2000; 44:1453-7.
23. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44:2118-25.
24. Richter SS, Diekema DJ, Heilmann KP, et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis 2003; 36:380-3.
25. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
26. Bisno AL, Stevens DL. Streptococcus pyogenes. In: Mandell GM, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005:2362-79.
27. Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998;26:1341-5.
28. Barry AL, Pfaller MA, Fuchs PC, Packer RP. In vitro activities of 21 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994; 38:2419-25.
29. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-6.
30. Perez-Trallero E, Marimon JM, Orden B, de Pablos M. Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain. Emerg Infect Dis 1999; 5:235-40.
31. Descheemaeker P, Chapelle S, Lammens C, et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneutnoniae isolates. J Antimicrob Chemother 2000; 45:167-73.
32. Reinert RR, Lutticken R, Sutcliffe JA, et al. Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother 2004; 48:1369-73.
33. Katz KC, McGreer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003; 47:2370-2.
34. Farrell DJ, Morrissey I, Bakker S, Felmingam D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolates from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50(Suppl 1):39-47.
35. Bemer-Melchior P, Juvin ME, Tassin S, Bryskier A, Schito GC, Drugeon HB. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 2000; 44:2999-3002.
36. O'Brien KL, Beall B, Barett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-99. Clin Infect Dis 2002; 35:268-76.
37. Li Z, Sakota V, Jackson D, Franklin AR, Beall B. Array of M protein gene subtypes in 1064 recent invasive group A Streptococcus isolates recovered from the active bacterial core surveillance. J Infect Dis 2003; 188:1587-92.
38. Shulman ST, Tanz RR, Kabat K, et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. Clin Infect Dis 2004; 39:325-32.
39. Yan SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44:3196-8.
40. Reinert RR, Lutticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical Streptococcus pyogenes isolate in Germany. Clin Microbiol Infect 2004; 10:659-62.
41. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005; 40:225-35.